THERAPY DOSSIER · th-f3a418b8358d

Bone marrow-derived mononuclear cells

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 9

7 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04528550 ↗Injury indicationPHASE2unknown

Intrathecal Transplantation of Autologous Bone Marrow-derived Mononuclear Cells for Traumatic Acute Spinal Cord Injury

Spinal Cord Injury

Enrolment: 45 · Results not recorded

NCT02923817 ↗Injury indicationPHASE2unknown

Phase I-II Clinical Trial Using Bone Marrow-derived Mononuclear Cells for Spinal Cord Injury

Spinal Cord Injuries

Enrolment: 30 · Results not recorded

NCT01575470 ↗Injury indicationPHASE1/PHASE2completed

Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells

Traumatic Brain Injury

Enrolment: 25 · Results not recorded

NCT02237547 ↗Injury indicationPHASE1/PHASE2withdrawn

Safety and Feasibility Study of Cell Therapy in Spinal Cord Injury (UC-MSC plus bone marrow mononuclear cells)

Spinal Cord Injury

Enrolment: 0 · Results not recorded

NCT02352077 ↗Injury indicationPHASE1unknown

Safety and Efficacy of NeuroRegen Scaffold With Bone Marrow Mononuclear Cells or Mesenchymal Stem Cells for Chronic Spinal Cord Injury Repair

Spinal Cord Injury

Enrolment: 30 · Results not recorded

NCT02028104 ↗Injury indicationPHASE1withdrawn

Open Label Study of Autologous Bone Marrow Mononuclear Cells in Traumatic Brain Injury

Traumatic Brain Injury

Enrolment: 0 · Results not recorded

NCT02027246 ↗Injury indicationPHASE1withdrawn

Autologous Bone Marrow Mononuclear Cell Therapy for Spinal Cord Injury

Spinal Cord Injury

Enrolment: 0 · Results not recorded

NCT02178657 ↗PHASE2completed

Intra-arterial Autologous Bone-marrow Mononuclear Cells Infusion for Acute Ischemic Stroke: Phase II Open-label Multicenter RCT

Ischemic Stroke

Enrolment: 76 · Results not recorded

NCT03080571 ↗PHASE1completed

Safety, Feasibility and Clinical Outcome of Intraarterial Infusion of Bone Marrow Derived Mononuclear Cells in Subacute Ischaemic Stroke

Ischemic Stroke · MCA Infarction

Enrolment: 20 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27473980 ↗2016Reported benefit

Evaluation of the survival of bone marrow-derived mononuclear cells and the growth factors produced upon intramedullary transplantation in rat models of acute spinal cord injury

RatSpinal cord injuryUnspecifiedSprague-DawleyMalen = 26Intramedullary transplantationImmediately after injury

Model: Acute traumatic spinal cord injury

Transplantation reduced demyelination and apoptosis at 3 days post-injury and improved hindlimb function at 7 days post-injury

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…